Vericel Corporation (VCEL)

US — Healthcare Sector
Peers: CLGN  KROS  MRUS  IPSC  CMRX  DAWN  XFOR  MREO  TERN  IDYA  SNDX  XNCR  RGNX  CRNX  STOK  PLRX  DYN  CYTK  RVMD  BPMC  RLAY 

Automate Your Wheel Strategy on VCEL

With Tiblio's Option Bot, you can configure your own wheel strategy including VCEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol VCEL
  • Rev/Share 4.7799
  • Book/Share 5.921
  • PB 7.3299
  • Debt/Equity 0.3349
  • CurrentRatio 5.0101
  • ROIC -0.0068

 

  • MktCap 2184886200.0
  • FreeCF/Share 0.8732
  • PFCF 50.1362
  • PE 727.2925
  • Debt/Assets 0.2331
  • DivYield 0
  • ROE 0.0109

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Vericel Corporation (VCEL) Q1 2025 Earnings Conference Call Transcript
VCEL
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral

Vericel Corporation. (NASDAQ:VCEL ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Eric Burns - VP, Finance and IR Nick Colangelo - CEO Joe Mara - CFO Conference Call Participants Ryan Zimmerman - BTIG Richard Newitter - Truist Securities Josh Jennings - TD Cowen Caitlin Cronin - Canaccord Mason Carrico - Stephens Operator Thank you for standing by.

Read More
image for news Vericel Corporation (VCEL) Q1 2025 Earnings Conference Call Transcript
Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates
VCEL
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative

Vericel Corporation (VCEL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.

Read More
image for news Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
VCEL
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for Trained Surgeons Second Quarter Total Revenue and MACI Revenue Growth Expected to be in the Low- to Mid-20% Range Full-Year 2025 Revenue Guidance Reaffirmed and Profitability Guidance Raised Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the …

Read More
image for news Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
VCEL
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Bank of America Securities 2025 Healthcare Conference at 12:20 p.m. ET (9:20 a.m. PT) on Wednesday, May 14, 2025.

Read More
image for news Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
VCEL
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22%

Read More
image for news Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results

About Vericel Corporation (VCEL)

  • IPO Date 1997-02-04
  • Website https://vcel.com
  • Industry Biotechnology
  • CEO Mr. Dominick C. Colangelo Esq.
  • Employees 357

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.